We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Intranasal Influenza Vaccine Adding to the Armamentarium for Influenza Control

Gregory A. Poland, MD; Robert Couch, MD
JAMA. 1999;282(2):182-184. doi:10.1001/jama.282.2.182.
Text Size: A A A
Published online


In the United States, national influenza vaccine recommendations have typically been based on the prevention of complications and death among high-risk persons. More recent is the increasing awareness that above and beyond the more severe individual medical consequences of influenza, enormous societal economic costs are associated with disruptions due to school and work absences and days of illness. In this issue of THE JOURNAL, Nichol et al1 report that use of a live, attenuated influenza virus (LAIV) vaccine, administered by intranasal spray to healthy, working adults (a group without a routine recommendation to receive influenza vaccine), was followed in the subsequent influenza epidemic season by a significant reduction in severe febrile illness, days lost from work, health care visits, and the medication use that accompanies these illnesses. Are these findings important? From an individual, medical, and public health point of view, the answer is clearly yes. Reductions in febrile illnesses, defined in various ways, ranged from approximately 13% to 27%, reductions in work days lost from 18% to 28%, and reductions in health care visits from 25% to 41%.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

11 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Influenza